Loading clinical trials...
Loading clinical trials...
A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter, First in Human Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Oral AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Conditions
Interventions
AUR107
Locations
37
India
HCG City Cancer Centre
Vijayawada, Andhra Pradesh, India
Omega Hospital
Visakhapatnam, Andhra Pradesh, India
Post-Graduate Institute of Medical Education and Research(PGIMER)
Chandigarh, Chandigarh, India
Apollo Hospital International Limited
Ahmedabad, Gujarat, India
Universal Superspeciality Hospital
Surat, Gujarat, India
Unique Hospital Multispeciality and Research Institute
Surat, Gujarat, India
Start Date
September 5, 2023
Primary Completion Date
January 1, 2027
Completion Date
June 1, 2027
Last Updated
April 17, 2026
Lead Sponsor
Aurigene Discovery Technologies Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions